Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Chim Acta ; 413(13-14): 1151-5, 2012 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-22465082

RESUMO

BACKGROUND: In hyperornithinemia-hyperammonemia-homocitrullinemia (HHH) syndrome, impaired ornithine transport across the mitochondrial membrane causes ornithine accumulation in cytoplasm. The resulting mitochondrial ornithine deficiency leads to reduced clearance of ammonia through the urea cycle. First described in 1969, no long-term follow-up has been reported. METHODS: Four patients were followed up for 11 to 38y. Diagnosis was made by plasma amino acid analysis using ion exchange chromatography, HPLC orotic acid measurement, and (14)C-ornithine incorporation study using cultured fibroblasts. DNA from fibroblasts was amplified and sequenced. Blood ammonia was controlled by restriction of protein intake. RESULTS: All patients had reduced (14)C-ornithine incorporation. Mutation analysis revealed two novel mutations in the ORNT1 gene. Neurologic outcome included memory loss, low IQ, tremor, spasticity of extremities, bladder incontinence, and abnormal gait. Neuroimaging revealed subcortical, cerebral and cerebellar atrophy, sparing the basal ganglia. Individual examination showed pyramidal signs, cerebellar signs, paraplegia, movement disorder, dystonia, and epilepsy. One patient had 3 pregnancies, one of which resulted in intrauterine growth retardation. CONCLUSIONS: Our patients expand the clinical phenotype of adults with HHH. Long-term follow-up showed serious neurologic outcomes in all patients; three patients clearly exhibited progression of neurologic dysfunction despite control of hyperammonemia. Intracellular ornithine deficiency may adversely affect brain functions.


Assuntos
Hiperamonemia/fisiopatologia , Distúrbios Congênitos do Ciclo da Ureia/fisiopatologia , Adulto , Sistemas de Transporte de Aminoácidos Básicos/genética , Aminoácidos/sangue , Cromatografia Líquida de Alta Pressão , Cromatografia por Troca Iônica , Análise Mutacional de DNA , Progressão da Doença , Feminino , Seguimentos , Humanos , Hiperamonemia/sangue , Hiperamonemia/genética , Masculino , Pessoa de Meia-Idade , Proteínas de Transporte da Membrana Mitocondrial , Ornitina/sangue , Ornitina/deficiência , Ornitina/genética , Fenótipo , Fatores de Tempo , Distúrbios Congênitos do Ciclo da Ureia/sangue , Distúrbios Congênitos do Ciclo da Ureia/genética
2.
Stroke ; 34(6): e51-4, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12738890

RESUMO

BACKGROUND AND PURPOSE: The introduction of cereal grain folic acid fortification in 1998 has reduced homocyst(e)ine (tHcy) concentrations in the US population. We performed a case-control study to determine the risk of stroke and transient ischemic attack (TIA) associated with tHcy and low vitamin status in a postfortification US sample. METHODS: Consecutive cases with new ischemic stroke/TIA were compared with matched controls. Fasting tHcy, folate, pyridoxal 5'-phosphate (PLP), B12, and MTHFR 677C-->T genotype were measured. RESULTS: Mean PLP was significantly lower in cases than controls (39.97 versus 84.1 nmol/L, P<0.0001). After stroke risk factors were controlled for, a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001) but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1). CONCLUSIONS: Low B6 but not tHcy was strongly associated with cerebrovascular disease in this postfortification, folate-replete sample.


Assuntos
Ácido Fólico/administração & dosagem , Homocisteína/sangue , Homocistina/sangue , Ataque Isquêmico Transitório/sangue , Acidente Vascular Cerebral/sangue , Vitamina B 6/sangue , Estudos de Casos e Controles , Comorbidade , Grão Comestível , Feminino , Ácido Fólico/sangue , Alimentos Fortificados , Humanos , Ataque Isquêmico Transitório/epidemiologia , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2) , Pessoa de Meia-Idade , Razão de Chances , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/genética , Fosfato de Piridoxal , Medição de Risco , Fatores de Risco , Albumina Sérica/análise , Acidente Vascular Cerebral/epidemiologia , Estados Unidos/epidemiologia , Vitamina B 12/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...